We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Merit Medical (MMSI) to Report Q2 Earnings: What's in Store?
Read MoreHide Full Article
Merit Medical Systems, Inc (MMSI - Free Report) is scheduled to report second-quarter 2018 earnings on Jul 23, after the market closes. The company’s acquisition-driven strategy is expected to boost growth by expanding existing product offerings across all business segments in the quarter. Strong prospects in the HeRO product line are a positive.
In the last reported quarter, Merit Medical’s adjusted earnings came in at 31 cents, which beat the Zacks Consensus Estimate by 6.9%. Earnings rose 10.7% from the prior-year quarter’s tally. In the quarter, worldwide revenues totaled $203 million on a reported basis, beating the Zacks Consensus Estimate by 4.6%. The company posted an average positive earnings surprise of 10.2% in the trailing four quarters.
For the quarter to be reported, the Zacks Consensus Estimate for revenues is pegged at $214.5 million, reflecting a rise of 15%. The same for adjusted earnings is at 40 cents, mirroring a 11.1% increase.
Let’s delve into the factors that are likely to impact Merit Medical’s upcoming quarterly results.
Acquisitions to Drive Growth
Merit Medical has been leveraging on bolt-on buyouts to drive inorganic growth. On May 2, the company announced a worldwide distribution agreement with NinePoint Medical, Inc and the development of a strategic alliance between the Merit Endotek division and NinePoint Medical.
The alliance is likely to combine the highly exclusive gastrointestinal and pulmonary medical devices from Merit Endotek with the ground-breaking Optical Coherence Tomography (OCT) platform from NinePoint Medical.
Leadership Change
Merit Medical witnessed a major change in its leadership in the second quarter. On May 31, the company announced that Bernard Birkett has resigned as the chief financial officer. In his replacement, Raul Parra, a veteran who has already served the company for more than eight years, has been appointed as the new interim chief financial officer. The company’s shares have significantly improved since then.
FDA Approvals
Of the major approvals, the company’s recently-approved Prelude Ideal product by the FDA deserves a mention. It is a unique vascular sheath. Strong demand for this product has bolstered the company’s prominence in the MedTech markets. Apart from Prelude Ideal, the company recently received a 510(k) for a distal access SYNC and the Merit Pursue Microcatheter.
Positive feedbacks and approvals from the top-notch regulatory bodies is likely to boost the top line in the second quarter with an expanded customer base. Notably, by the end of the first quarter of 2018, Merit Medical confirmed that it has almost 50 active R&D products in its portfolio.
HeRO to Drive Growth
Merit Medical’s HeRO product line has been a key contributor to growth. HeRO Graft, Super HeRO Adapter and HeRO Ally Revision Kit are the three platforms within the HeRO family of dialysis devices. Considering the solid global prospects of hemodialysis solutions, the HeRO product line is likely to provide Merit Medical with a competitive edge in the MedTech markets in the quarter to be reported.
Earnings Whispers
Per our proven model, a stock needs to have a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to deliver a positive earnings surprise in the fiscal third quarter. This is not the case here as you will see below.
Zacks ESP: Merit Medical has an Earnings ESP of -7.11. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company carries a Zacks Rank #2.
Please note that we caution against stocks with a Zacks Rank #4 or 5 (Sell rated) going into the earnings announcement, especially when the company is seeing negative estimate revision.
Stocks Worth a Look
Here are a few medical stocks worth considering as they have the right combination of elements to post an earnings beat this quarter.
Bio-Rad Laboratories (BIO - Free Report) has an Earnings ESP of +7.41% and a Zacks Rank of 2.
Baxter International Inc (BAX - Free Report) has an Earnings ESP of +0.42% and a Zacks Rank of 2.
DexCom, Inc. (DXCM - Free Report) has an Earnings ESP of +12.84% and a Zacks Rank of 3.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
Image: Bigstock
Merit Medical (MMSI) to Report Q2 Earnings: What's in Store?
Merit Medical Systems, Inc (MMSI - Free Report) is scheduled to report second-quarter 2018 earnings on Jul 23, after the market closes. The company’s acquisition-driven strategy is expected to boost growth by expanding existing product offerings across all business segments in the quarter. Strong prospects in the HeRO product line are a positive.
In the last reported quarter, Merit Medical’s adjusted earnings came in at 31 cents, which beat the Zacks Consensus Estimate by 6.9%. Earnings rose 10.7% from the prior-year quarter’s tally. In the quarter, worldwide revenues totaled $203 million on a reported basis, beating the Zacks Consensus Estimate by 4.6%. The company posted an average positive earnings surprise of 10.2% in the trailing four quarters.
For the quarter to be reported, the Zacks Consensus Estimate for revenues is pegged at $214.5 million, reflecting a rise of 15%. The same for adjusted earnings is at 40 cents, mirroring a 11.1% increase.
Merit Medical Systems, Inc. Price and Consensus
Merit Medical Systems, Inc. Price and Consensus | Merit Medical Systems, Inc. Quote
Let’s delve into the factors that are likely to impact Merit Medical’s upcoming quarterly results.
Acquisitions to Drive Growth
Merit Medical has been leveraging on bolt-on buyouts to drive inorganic growth. On May 2, the company announced a worldwide distribution agreement with NinePoint Medical, Inc and the development of a strategic alliance between the Merit Endotek division and NinePoint Medical.
The alliance is likely to combine the highly exclusive gastrointestinal and pulmonary medical devices from Merit Endotek with the ground-breaking Optical Coherence Tomography (OCT) platform from NinePoint Medical.
Leadership Change
Merit Medical witnessed a major change in its leadership in the second quarter. On May 31, the company announced that Bernard Birkett has resigned as the chief financial officer. In his replacement, Raul Parra, a veteran who has already served the company for more than eight years, has been appointed as the new interim chief financial officer. The company’s shares have significantly improved since then.
FDA Approvals
Of the major approvals, the company’s recently-approved Prelude Ideal product by the FDA deserves a mention. It is a unique vascular sheath. Strong demand for this product has bolstered the company’s prominence in the MedTech markets. Apart from Prelude Ideal, the company recently received a 510(k) for a distal access SYNC and the Merit Pursue Microcatheter.
Positive feedbacks and approvals from the top-notch regulatory bodies is likely to boost the top line in the second quarter with an expanded customer base. Notably, by the end of the first quarter of 2018, Merit Medical confirmed that it has almost 50 active R&D products in its portfolio.
HeRO to Drive Growth
Merit Medical’s HeRO product line has been a key contributor to growth. HeRO Graft, Super HeRO Adapter and HeRO Ally Revision Kit are the three platforms within the HeRO family of dialysis devices. Considering the solid global prospects of hemodialysis solutions, the HeRO product line is likely to provide Merit Medical with a competitive edge in the MedTech markets in the quarter to be reported.
Earnings Whispers
Per our proven model, a stock needs to have a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to deliver a positive earnings surprise in the fiscal third quarter. This is not the case here as you will see below.
Zacks ESP: Merit Medical has an Earnings ESP of -7.11. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company carries a Zacks Rank #2.
Please note that we caution against stocks with a Zacks Rank #4 or 5 (Sell rated) going into the earnings announcement, especially when the company is seeing negative estimate revision.
Stocks Worth a Look
Here are a few medical stocks worth considering as they have the right combination of elements to post an earnings beat this quarter.
Bio-Rad Laboratories (BIO - Free Report) has an Earnings ESP of +7.41% and a Zacks Rank of 2.
Baxter International Inc (BAX - Free Report) has an Earnings ESP of +0.42% and a Zacks Rank of 2.
DexCom, Inc. (DXCM - Free Report) has an Earnings ESP of +12.84% and a Zacks Rank of 3.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>